Skip to main content

Table 1 (abstract A38). Characteristics of biologic switchers in the CARRA Registry

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

  All 1st Biologic Switchers (N = 349) Switch for Inefficacy/Disease Flare n= 202 Switch for all other reasons n=147 p value
Reason for switch: n, %     xx
Adverse event 11 (3) 0 11 (7)  
Ineffective/Disease Flare 202 (58) 202 (100) 0  
Infusion/Injection reaction 7 (2) 0 7 (5)  
Mild AE/Intolerance of Delivery mode 32 (9) 0 32 (22)  
other 66 (19) 0 66 (45)  
Unknown/Incomplete data 31 (9) 0 31 (21)  
Age (years) median, IQR 10 (7-13) 11 (8-13) 9 (6-13) 0.0099
Female (N, %) 274 (79) 157 (78) 117 (80) ns
Time from start medication to switch (start 2nd) (days) median, IQR 394 (192-891) 306 (175-633) 660 (252-1233) <0.0001
Elapsed time from discontinuation of 1st biologic to start of 2nd biologic (days) median, IQR 0 (0-21) 0 (0-7) 1 (0-80) <0.0001
Calendar year of switch: median, range, IQR 2016 (2015-2017) 2016 (2015-2017) 2016 (2014-2017) ns
Type of switch: n,%     0.03
Etanercept to other TNF 221 (63) 130 (64) 91 (62)  
Etanercept to non TNF 33 (10) 19 (9) 14 (10)  
Other TNF to Etanercept 28 (8) 10 (5) 18 (12)  
Other TNF to non TNF 21 (6) 16 (8) 5 (3)  
Non TNF to Etanercept 7 (2) 1 (1) 6 (4)  
Non TNF to other TNF 4 (1) 3 (1.5) 1 (1)  
Non TNF to non TNF 5 (1) 3 (1.5) 2 (1)  
Other TNF to other TNF 30 (9) 20 (10) 10 (7)  
  1. IQR, interquartile range; AE, adverse event; TNF, tumor necrosis factor inhibitor